Screener
Disc Medicine IRON DISC Three Four Zero Five — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:33 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205192
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Bitopertin program external expense | $(9,340) | $(8,435) |
| DISC-0974 program external expense | (8,109) | (6,121) |
| DISC-3405 program external expense | (9,187) | (1,668) |
| Other external research and development expense | (2,165) | (1,832) |
| Internal and other research and development expense | (11,312) | (6,748) |
| Commercial expense | $(8,434) | $(1,921) |
| General and administrative expense | $(9,031) | $(6,858) |
| Stock-based compensation expense | $(11,946) | $(6,363) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Disc Medicine's DISC three four zero five — research and development expense?
- Disc Medicine (IRON) reported DISC three four zero five — research and development expense of $9.19M in Q1 2026.
- How has Disc Medicine's DISC three four zero five — research and development expense changed year-over-year?
- Disc Medicine's DISC three four zero five — research and development expense increased by 450.8% year-over-year, from $1.67M to $9.19M.
- What is the long-term trend for Disc Medicine's DISC three four zero five — research and development expense?
- Over 2 years (2023 to 2025), Disc Medicine's DISC three four zero five — research and development expense has grown at a -6.3% compound annual growth rate (CAGR), from $20.17M to $17.69M.
- What does DISC three four zero five — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research and development activities for the specific clinical or preclinical therapeutic candidate identified as DISC-3405. It captures the investment in scientific discovery, clinical trial execution, and regulatory preparation necessary to advance this specific asset through the drug development pipeline. Monitoring this expense provides insight into the capital allocation strategy and the pace of development for this particular hematologic program.
Ask your AI about Disc Medicine's disc three four zero five — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude